{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:26:52Z","timestamp":1761920812743,"version":"3.37.3"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Services, State Government of Victoria","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-AnyM13\u2192M25) in the CYD14 (2\u201314-y-olds) and CYD15 (9\u201316-y-olds) phase 3 trials. Fifty percent plaque reduction neutralization test (PRNT50) titers are a potential surrogate for immunobridging VE to adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using PRNT50 calibration datasets, we applied immunobridging approaches using baseline and\/or M13 PRNT50 titers to estimate VE against VCD-DENV-AnyM0\u2192M25 and against hospitalized VCD (HVCD)-DENV-AnyM0\u2192M72 in hypothetical 18\u201345-y-old and 46\u201350-y-old CYD14 and CYD15 cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline and M13 geometric mean PRNT50 titers were greater in 18\u201345-y-olds and in 46\u201350-y-olds vs 9\u201316-y-olds for most comparisons. Estimated VE (95% CIs against VCD-DENV-AnyM0\u2192M25 ranged from 75.3% to 90.9% (52.5% to 100%) for 18\u201345-y-olds and 74.8% to 92.0% (53.4% to 100%) for 46\u201350-y-olds. Estimated VE (95% CIs) against HVCD-DENV-AnyM0\u2192M72 ranged from 58.8% to 78.1% (40.9 to 98.9%) for 18\u201345-y-olds and 57.2% to 78.4% (40.5 to 97.6%) for 46\u201350-y-olds. Corresponding predictions among baseline-seropositive individuals yielded comparable or higher VE estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>VE M0\u2192M25 against DENV-Any and VE against HVCD-DENV-AnyM0\u2192M72 are both expected to be higher in 18\u201345 and 46\u201350-y-olds vs CYD14 and CYD15 9\u201316-y-olds.<\/jats:p><\/jats:sec>","DOI":"10.1093\/trstmh\/traa154","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T21:38:17Z","timestamp":1605821897000},"page":"750-763","source":"Crossref","is-referenced-by-count":3,"title":["Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children\/adolescents to adults in highly endemic countries"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-7502","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"first","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Moodie","sequence":"additional","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Juraska","sequence":"additional","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay N","family":"Carpp","sequence":"additional","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Chambonneau","sequence":"additional","affiliation":[{"name":"Global Biostatistical Sciences, Sanofi Pasteur, Marcy-l'Etoile, 69280, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana L","family":"Coronel","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Mexico City, 04000, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo H","family":"Dayan","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Swiftwater, PA, 18370, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A","family":"DiazGranados","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Marcel M\u00e9rieux, Marcy l'Etoile, 69280, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter B","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Vaccine and Infec tious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA"},{"name":"Department of Biostatistics, University of Washington, Seattle, WA, 98195, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"issue":"7446","key":"2021063023535288300_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"issue":"8","key":"2021063023535288300_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"2021063023535288300_bib3","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat Microbiol"},{"volume-title":"Dengue and severe dengue","author":"World Health Organization","key":"2021063023535288300_bib4"},{"issue":"9951","key":"2021063023535288300_bib5","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"2021063023535288300_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2021063023535288300_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"volume-title":"Meeting of the Strategic Advisory Group of Experts on immunization","year":"2018","author":"World Health Organization","key":"2021063023535288300_bib8"},{"key":"2021063023535288300_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-323-35761-6.00003-1","article-title":"Correlates of Protection","volume-title":"Plotkin's Vaccines","author":"Plotkin","year":"2018","edition":"7"},{"issue":"5","key":"2021063023535288300_bib10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/infdis\/jix609","article-title":"Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America","volume":"217","author":"Moodie","year":"2018","journal-title":"J Infect Dis"},{"issue":"1","key":"2021063023535288300_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4269\/ajtmh.18-0534","article-title":"Bridging efficacy of a tetravalent dengue vaccine from children\/adolescents to adults in highly endemic countries based on neutralizing antibody response","volume":"101","author":"Gilbert","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2021063023535288300_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1515\/em-2015-0007","article-title":"Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy","volume":"5","author":"Gilbert","year":"2016","journal-title":"Epidemiol Methods"},{"issue":"7","key":"2021063023535288300_bib13","first-page":"162","article-title":"Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children","volume":"3","author":"Tran","year":"2012","journal-title":"J Vaccines Vaccination"},{"issue":"5","key":"2021063023535288300_bib14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"2021063023535288300_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/biostatistics\/kxy074","article-title":"Inference on treatment effect modification by biomarker response in a three-phase sampling design","volume":"21","author":"Juraska","year":"2018","journal-title":"Biostatistics"},{"issue":"3","key":"2021063023535288300_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1541-0420.2011.01722.x","article-title":"Assessing treatment-selection markers using a potential outcomes framework","volume":"68","author":"Huang","year":"2012","journal-title":"Biometrics"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/7\/750\/38843307\/traa154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/trstmh\/article-pdf\/115\/7\/750\/38843307\/traa154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T22:30:44Z","timestamp":1669674644000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/115\/7\/750\/6053819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,28]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/traa154","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"type":"print","value":"0035-9203"},{"type":"electronic","value":"1878-3503"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2020,12,28]]}}}